Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Another Weeeeeeeeeeeeeeeeeeeeeeee investment move.
$CLOV
Added to my stash this am will accumulate up on this one started investing in the low 2.00s
$XXII
20.00 Painted another massive hit on options this week.
$CLOV
Get them apes destroy Shortie!!!
Going to Wendy’s for breakfast lol lmao
$CLOV
Your welcome Diamond Hands Lasers Eyes!
PDSB May 2021 Biz Presentation.
https://www.pdsbiotech.com/images/pdf/presentation/2021/may/PDSB_Corporate_Overview_-_May_24_2021_v5.pdf
PDSB website.
https://www.pdsbiotech.com/
52 week low 1.12
52 week high 13.48
$PDSB
Hi bears lol lmao.
https://i.pinimg.com/originals/58/80/ef/5880ef672981142ff41ded2c0c25782c.gif
$PDSB
Nice recovery after a 200% move up in a few weeks! Anyone who talks this stock down needs help one of the best performers small cap bios in the market.
120k shares Long & Strong
$PDSB
Going higher you can make book on that!!
BB
My 19.00's from a few weeks back look like the golden ticket again banked on options as well! Easy breezy!!!!
$SPCE
Loaded in the 10.00 Range 16 months ago still holding half my stash Freebies that's what I do is buy low & make bank!
$NVAX
What a beast in since 34.00 for 4500 I'm not selling.
Always early!!
it's a stock pickers market and I'm one hell of a stock picker!
$MRNA
Hold the line!
$MNMD
Re Adjusting my small cap bio portfolio sold a few positions yesterday and added a huge chunk in INFI
$INFII
Added 22k shares at 8.34-8.42 average. 50% FIB RESET after a $200% move from low 4.00s to 13.00 Plus in two weeks was needed nice reset. Don't hate the player hate the game.
122k Shares long and down payment on a vacation home in Maui in since the lows of the year. Thank you PDSB
Biotechs heating up across the board.
$PDSB
MM game plan is weak and pathetic tactics low brow I smell blood time to go in for the kill.
I see the angles before they are being played.
Quiet name waking up.
Always early!
$HEPA
Feed me doubled down on recent lows $3.10-$3.22 range last few weeks easy breezy!!
$MNMD
Taking Meme Options profits here and spreading it over my half dozen brokerage accounts also family and friends & two family offices who banked on PDSB taking positions. HEPA HEPA is trading similar pattern too PDSB in the $2.00 Range this is going to be fun. Sit back accumulate and lock up your shares. This is a home run in the making.
No Nash drug approved. Upward Price targets are mind numbing from these levels. This is a multi billion dollar cap in. the making. MM supressing the share price while most small bios are up makes my Spyder senses tell me HEPA explosive move is coming HEPA is about to drop some hammers lots of catalyst on tap!.
$HEPA
Pat Mayo presented this at the recent Global NASH Congress. If you look at pages 22-25, you'll see what AI-POWR has projected for the 225mg cohort.
By the way, even the 75mg results were exceptional, and way more than good enough to move on to Phase IIb, which they plan to open in Q4.
In just 28 days at the low dose, CRV431 results were as good as what Madrigal's P3 lead NASH drug took 12 weeks to accomplish.
https://12ewye24eigk3g5kwa2dxjzm-wpengine.netdna-ssl.com/wp-content/uploads/2021/04/4thGlobal_NASH_Congress_Draft_20Apr2021_FINAL-1.pdf
MDGL 1.7 Billion Market Cap 275 Million in cash
HEPA 143 Million Market Cap 120 Million in cash
$HEPA
The gift that keeps on giving the options are a wealth creator on BB
$BB
The set up looks great!
PDSB May 2021 Biz presentation.
https://www.pdsbiotech.com/images/pdf/presentation/2021/may/PDSB_Corporate_Overview_-_May_24_2021_v5.pdf
PDSB Website:
https://www.pdsbiotech.com
$PDSB
There hadn't been much of anything on the 1-month since
September, until that Bullish reversal Hammer in May.
Bodes well for the big picture...
By the way, some competitors' greatly inferior NASH drugs are being valued in the billions. Just a 1 Billion market cap for Hepion makes for $13.12 a share, and CRV431 is going to eventually treat many other indications, some with treatment markets in the many tens of billions
There are 76m shares out. >95% institutional ownership.
No filings were submitted for ~70% of the 64m shares bought at the November and February offerings, meaning the vast majority was concealed.
Before institutions bought 64m shares at those offerings, there were 12m shares out, with 3m in the public float. So, direct holders had ~9m shares of that, and tutes got 64m at the offerings, which possibly left ~3m for retail then.
MDGL was $300.00 a year and half ago with 4.5 Billion MC Now trading at 102.00 1.7 Billion market cap 1.7 Billion
HEPA CRV431 Phase 2B later this year. 145 Million market cap 120 in Cash Under 5 million quarter burn rate per quarter pretty low. We talk about all the indications for which CRV431 appears to have tremendous potential, and some of them have enormous global treatment markets, including NASH itself at tens of billions of dollars and with a huge CAGR, but let's not lose sight of the fact that there is currently no approved treatment for NASH, so with a fat score in the 225mg cohort, the house could soon be rockin'!!
HEPA IN-HOUSE
ARTIFICIAL INTELLIGENCE PROGRAM.
Multi-omics analyses – 25,000 data points per patient.
Identify biomarkers that predict response to CRV431.
Optimize and de-risk clinical trials through patient matching to CRV431 – precision medicine.
HEPA June 2 Biz Presentation:
https://hepionpharma.com/wp-content/uploads/2021/06/Corporate-deck-June-2021-FINAL.pdf
4th Global NASH Congress Presentation:
https://12ewye24eigk3g5kwa2dxjzm-wpengine.netdna-ssl.com/wp-
content/uploads/2021/04/4thGlobal_NASH_Congress_Draft_20Apr2021_FINAL-1.pdf
Tackling Chronic Liver Disease - CRV431 Mechanism of Action.
Don't sleep on this one. I helped make people big money on PDSB HEPA is the next monster runner with a 140 million market cap & 120 Million in cash
Always early!
HIGHLIGHTS
Oral, once-daily, multi-modal drug candidate – CRV431
Clinical Phase 2a NASH trial completing Q2
Clinical Phase 2b NASH trial planned for Q4 2021 start
Strong safety/tolerability profile in preclinical and Phase 1
Anti-fibrotic, anti-inflammatory, cytoprotective, anti-viral, anti-cancer, and metabolic regulation - all by cyclophilin inhibition (MOA)
Artificial Intelligence Platform (AI-POWRTM)
~30 years experience in cyclophilin inhibitor development
Core team discovered and developed voclosporin for transplantation and autoimmune disease (FDA approved Jan 2021)
Robust IP (including US, Europe, Australia, Canada, China, Japan, Korea)
June 2 Hepa Biz Presentation
https://hepionpharma.com/wp-content/uploads/2021/06/Corporate-deck-June-2021-FINAL.pdf
Nash congress Presentation
https://12ewye24eigk3g5kwa2dxjzm-wpengine.netdna-ssl.com/wp-content/uploads/2021/04/4thGlobal_NASH_Congress_Draft_20Apr2021_FINAL-1.pdf
HEPA Ai POWR PLATFORM:
Multi-omics analyses – 25,000 data points per patient
Identify biomarkers that predict response to CRV431
Optimize and de-risk clinical trials through patient matching to CRV431 – precision medicine
https://hepionpharma.com/ai-powr/
CRV431 Tackling Chronic Liver Disease - CRV431 Mechanism of Action
Great Post!
Careful bears shorting this one bears one of the best performing stocks of 2021 BOOMAGE!
Hi bears lol lmao.
https://i.pinimg.com/originals/58/80/ef/5880ef672981142ff41ded2c0c25782c.gif
$PDSB
We talk about all the indications for which CRV431 appears to have tremendous potential, and some of them have enormous global treatment markets, including NASH itself at tens of billions of dollars and with a huge CAGR, but let's not lose sight of the fact that there is currently no approved treatment for NASH, so with a fat score in the 225mg cohort, the house could soon be rockin'!!
$HEPA
HEPA put it on your radars massive upside ROI from these levels.
June 2 HEPA Biz Presentation just out!
https://hepionpharma.com/wp-content/uploads/2021/06/Corporate-deck-June-2021-FINAL.pdf
Always Early!
NASH MARKET IS 13 Billion next few years quarter of the population has a fatty liver NASH numbers are nearing 20 million in the USA alone.
My expertise is finding micro cap biotechs with strong technology well funded and top tier team behind them for 1000-2000% moves!
We ripped Ripped through 1.75, and you're probably gonna start blowing short stops.
Keep in mind, those short stops become market buy orders when they get hit, so don't be surprised if the price takes a pretty sizable move up!
NCBI just put it up today, two full weeks after publication
I see extraordinarily high potential for a partnership with Gilead, based on the combo study in HCV.
Hepion and Gilead working on a potential clinical study design.
Gilead's product is FDA approved, and clinical studies evaluating the potential to safely enhance clinical efficacy of FDA approved products present a potentially RAPID PATH TO COMMERCIALIZATION!
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8136729/
HEPA CRV431 Multiple Benefits Through Cyclophilin Antagonism Nash 13 Billion dollar market.
Cyclophilin enzymes regulate the structure and activity of many proteins throughout the body
PDSB next few weeks and months and years ahead will be fun to be a key shareholder of this company.
ASCO next week!
$PDSB
NASH HEPA & MDGL still standing while the others have failed.
I'll put it in a nutshell for you. None of the other Nash indications have anywhere near the anti-fibrotic properties that HEPA CRV431 does, and fibrosis is huge.
If you want to beat NASH altogethet CRV431 dominates the fibrosis element.
What excites me about the 225mg dose is not so much the fibrosis element, in that I'm confident it takes things even much further there, but I expect it might show significant improvement in other measurements
I'll try to post some fibrosis stuff this week, so that there's a better understanding of it, starting with what exactly it is, and what causes it.
There are not a lot of approaches to dealing with it, and most aren't panning out, so I'll do my best to highlight what appears to be one of the greatest advantages of HEPA CRV431
Intercept causes liver damage and is going backwards with FDA. Their 2a studies were also somewhat predictive of their current problems. They also tried to hide this from their investors by burying the latest issues in the middle of I think a quarterly filing. NGM just abandoned their Nash study after its 2b study did not meet endpoints...MDGl phase 2a study was good but it’s numbers were basically same as Hepions 75 mg dosing for only 28 days...MDGL dosing was 12 weeks...So Hepions 225 mg results will knock MDGl 2a results out of the water.
1/4 people in the USA have a fatty liver NASH market next few years 13 Billion in the USA no approved drugs for this indication yet.
HEPA 140 million market cap 120 million in cash phase 2B second half 2021
MDGL 1.6 Billion market cap 300 million cash phase 3
Tackling Chronic Liver Disease - CRV431 Mechanism of Action
Hepion Tackles NASH in Phase 2 with Cyclophilin Inhibitor CRV431 | Interview with HEPA CEO Robert Foster
AI power platform and CRV431 are both the most efficient ways of attack of disease processes. The AI platform saves billions by identifying through genomic and proteomic computer data driven analysis the therapies which will
work prior to spending billions on multiple patient population trials. Hepa will be a very historic story. with the preface being a 5th generation computer to begin the AI power platform and Robert Foster, CEO of HEPA, who discovered Voclosporin. Voclosprin inhibits autoimmune rejection of transplants and similar inhibition of Autoimmune disorders, recently approved in tx of Lupus. The inhibition associated w/ voclosporin runs on similar genomic and proteomic path as Cyclophilin A which CRV431 inhibits.
Cyclophilin A is spreader of m.myeloma, spreads fibrosis inside the kidneys, lungs, liver, heart. We haven’t begun to discuss the other 9 or 10 cyclophilins CRV431 inhibits.
Next HEPA new CMO chief medical officer Todd Hobbs spent 17 years with Novo Nordisk, a USD 185B pharmaceutical behemoth, and you can damn well bet that he didn't leave his VP/CMO position there to come to tiny Hepion to play tiddlywinks.
All the signs are right in front of our faces. What's going on behind the scenes has something to do with Novo Nordisk and/or Gilead.
There's simply too much benefit coming from whatever the hell they're cooking up with Hepion, and there's a damn good reason they were able to get institutional investors to put up eighty eight million dollars in February!
HEPA June 02 Biz Presentation.
https://hepionpharma.com/wp-content/uploads/2021/06/Corporate-deck-June-2021-FINAL.pdf
$HEPA
You haven't seen anything yet anything under $2.00 is a gift from the stock gods new millionaires will be potentially made at these levels with some serious skin in the game. IMO
Remember I brought you NVAX under $10.00 and PDSB in the low $2.00 range in the last 12 months HEPA has the same type of massive upside!
HEPA a billion dollar company in the making. Sit back and enjoy the show and lock up your shares sky high good till cancelled months out.
Todd Hobbs the New chief medical officer at HEPA spent 17 years with Novo Nordisk, a USD 183 Billion pharmaceutical behemoth, and you can damn well bet that he didn't leave his VP/CMO position there to come to tiny Hepion to play tiddlywinks.
Former Novo Nordisk Executive, Dr. Todd M. Hobbs, Joins Hepion Pharmaceuticals as Chief Medical Officer
https://www.biospace.com/article/releases/former-novo-nordisk-executive-dr-todd-m-hobbs-joins-hepion-pharmaceuticals-as-chief-medical-officer/
Lots of catalysts and hammers the HEPA team is about to drop!
HEPA NASH Phase 2B CRV431 trial no approved FDA drug for NASH 13 billion dollar market.
Yes small Biotech companies like $PDSB & $HEPA with bleeding cutting edge technology and great management teams will make people fortunes.You can make book on that!
$PDSB
Just the beginning. Got you early on this one!
$HEPA
Todd Hobbs the New chief medical officer at HEPA spent 17 years with Novo Nordisk, a USD 183 Billion pharmaceutical behemoth, and you can damn well bet that he didn't leave his VP/CMO position there to come to tiny Hepion to play tiddlywinks.
All the signs are right in front of our faces. What's going on behind the scenes has something to do with Novo Nordisk and/or Gilead.
There's simply too much benefit coming from whatever they're cooking up with Hepion, and there's a great reason they were able to get institutional investors to put up eighty eight million dollars in February!!
Former Novo Nordisk Executive, Dr. Todd M. Hobbs, Joins Hepion Pharmaceuticals as Chief Medical Officer
https://www.biospace.com/article/releases/former-novo-nordisk-executive-dr-todd-m-hobbs-joins-hepion-pharmaceuticals-as-chief-medical-officer/
HEPA 130 Million market cap
HEPA 120 million in CASH
$HEPA
up 17.% today up 1300% from the 52 week low of $1.12
Shorting this stock would be the dumbest move of all time.
$PDSB
Going to be huge!!! Accumulating here! Potential supernova like here, this will go parabolic sooner than later Same as when I called PDSB & NVAX a year ago for 1000% & 2000% gains respectively. HEPA drug is safer and more effective than MDGL 1.7 Billion market cap Hepa 130 million market cap 120 Million in cash.
HEPA Tackling Chronic Liver Disease - CRV431 Mechanism of Action NASH 13 Billion dollar market
HEPA stock at these levels is a wealth creator.
HEPA There are 76m shares out. >95% institutional ownership.
No filings were submitted for ~70% of the 64m shares bought at the November and February offerings, meaning the vast majority was concealed.
Before institutions bought 64m shares at those offerings, there were 12m shares out, with 3m in the public float. So, direct holders had ~9m shares of that, and tutes got 64m at the offerings, which possibly left ~3m for retail then.
HIGHLIGHTS
STATUS, EXPERIENCE, RESOURCES
Oral, once-daily, multi-modal drug candidate – CRV431
Clinical Phase 2a NASH trial completing Q2
Clinical Phase 2b NASH trial planned for Q4 2021 start
Strong safety/tolerability profile in preclinical and Phase 1
Anti-fibrotic, anti-inflammatory, cytoprotective, anti-viral, anti-cancer, and metabolic regulation - all by cyclophilin inhibition (MOA)
Artificial Intelligence Platform (AI-POWRTM)
~30 years experience in cyclophilin inhibitor development
Core team discovered and developed voclosporin for transplantation and autoimmune disease (FDA approved Jan 2021)
Robust IP (including US, Europe, Australia, Canada, China, Japan, Korea)
OBJECTIVES
Efficacy of once daily (qd) oral dosing of CRV431 in biopsy proven NASH F2 and F3 patients compared to placebo
1-point reduction in fibrosis score in liver biopsies (pathologist and AI read)
AI-POWR? identification of biomarkers of CRV431 response from multi-omics, clinical labs, and other trait data
Multi-Center, triple-blind, placebo-controlled (2:1), study
Liver biopsies, MRE scans, Fibroscan, ALT, AST, Pro-C3, ELF-Score, fibrosis biomarkers, lipidomics, genomics, proteomics
NASH 13 Billion dollar market
HEPA 130 million market cap
HEPA 120 Million in CASH
$HEPA
Another 52 Week High KABOOMAGE!
Beast mode 2.0
$PDSB
Nice! to see you coming on board! Hope all is well!
Also took out the 50 EMA at 1.76
Grinding away!
$HEPA
June 2 HEPA Biz Presentation just out!
https://hepionpharma.com/wp-content/uploads/2021/06/Corporate-deck-June-2021-FINAL.pdf
HEPA Loading up for a big move!
Always Early!
Primed to see massive upside from these bottom levels.
My expertise is finding micro cap biotechs with strong technology well funded and top tier team behind them for 1000-2000% moves!
Rip through 1.75, and you're probably gonna start blowing short stops.
Keep in mind, those short stops become market buy orders when they get hit, so don't be surprised if the price takes a pretty sizable move up!
NCBI just put it up today, two full weeks after publication
I see extraordinarily high potential for a partnership with Gilead, based on the combo study in HCV.
Hepion and Gilead working on a potential clinical study design.
Gilead's product is FDA approved, and clinical studies evaluating the potential to safely enhance clinical efficacy of FDA approved products present a potentially RAPID PATH TO COMMERCIALIZATION!
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8136729/
CRV431 Multiple Benefits Through Cyclophilin Antagonism Nash 13 Billion dollar market.
Cyclophilin enzymes regulate the structure and activity of many proteins throughout the body
NCBI just put it up today, two full weeks after publication
I see extraordinarily high potential for a partnership with Gilead, based on the combo study in HCV.
Hepion and Gilead working on a potential clinical study design.
Gilead's product is FDA approved, and clinical studies evaluating the potential to safely enhance clinical efficacy of FDA approved products present a potentially RAPID PATH TO COMMERCIALIZATION!
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8136729/
So much going on HEPA wide array of indications in the works.
$HEPA